Details
Stereochemistry | ACHIRAL |
Molecular Formula | C9H8O2 |
Molecular Weight | 148.1586 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)\C=C\C1=CC=CC=C1
InChI
InChIKey=WBYWAXJHAXSJNI-VOTSOKGWSA-N
InChI=1S/C9H8O2/c10-9(11)7-6-8-4-2-1-3-5-8/h1-7H,(H,10,11)/b7-6+
Molecular Formula | C9H8O2 |
Molecular Weight | 148.1586 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Optical Activity | NONE |
Cinnamic acid is a polyphenol found in cinnamon oil and used in commercial flavorings. Recent studies have shown the pharmacological properties of cinnamic acid and its derivatives, including hepatoprotective, anti-oxidant, and anti-diabetic activities. In preclinical studies cinnamic acid demonstrated to be a promising candidate for the treatment ob obesity and diabetes. The mechanism of action of cinnamic acid in obesity is explained by its ability to inhibit lipases and ACE (angiotensin-converting enzyme). However, there are several hypotesis regarding the effect of cinnamic acid in diabetes: cinnamic acid enhances glucose-induced insulin secretion, prevents palmitic acid-induced lipotoxicity, inhibits palmitic acid-induced alteration of lipogenic gene and protein expression (AMPK, SREBP-1c, FAS, ACC), inhibits DPP IV, exhibits an additive effect on the uptake of glucose, stimulates adiponectin secretion, etc.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: Lipid digestive enzymes Sources: https://www.ncbi.nlm.nih.gov/pubmed/26139902 |
|||
Target ID: P12821 Gene ID: 1636.0 Gene Symbol: ACE Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/26139902 |
|||
Target ID: P27487 Gene ID: 1803.0 Gene Symbol: DPP4 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/28230764 |
|||
Target ID: P18031 Gene ID: 5770.0 Gene Symbol: PTPN1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/26139902 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Structure-activity relationships for a large diverse set of natural, synthetic, and environmental estrogens. | 2001 Mar |
|
Organic acids in the second morning urine in a healthy Swiss paediatric population. | 2003 Dec |
|
Prediction of estrogen receptor agonists and characterization of associated molecular descriptors by statistical learning methods. | 2006 Nov |
|
Phenolic acids suppress adipocyte lipolysis via activation of the nicotinic acid receptor GPR109A (HM74a/PUMA-G). | 2009 May |
|
Biochemical mechanism of caffeic acid phenylethyl ester (CAPE) selective toxicity towards melanoma cell lines. | 2010 Oct 6 |
|
Structure-activity relationships of trans-substituted-propenoic acid derivatives on the nicotinic acid receptor HCA2 (GPR109A). | 2011 May 1 |
Patents
Sample Use Guides
In a preclinical study cinnamic acid was administered orally to rats at a dose of 5 and 10 mg/kg (diabetes model). In a preclinical model of obesity/hypertension cinnamic acid was given at 30 mg/kg/day.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19685889
To determine the effect of cinnamic acid on glucose uptake FL83B cells were suspended in HBSS
containing 5 mM glucose and 5.0 ug/mL insulin. Each 20 uL aliquot of the cell suspension was incubated with the mixture of 20 uL of 12.5 uM cinnamic acid and 20 uL of HBSS at 37 celsius degrees for 30 min with constant shaking. Glucose uptake in mouse liver FL83B cells treated with cinnamic acid (472.8 (8.9 cpm/mg of protein) is
2.3 and 2.0 times of the basal uptake value (240.6 (20.2 cpm/mg of protein), respectively.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:46:44 GMT 2023
by
admin
on
Fri Dec 15 16:46:44 GMT 2023
|
Record UNII |
U14A832J8D
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
DSLD |
2727 (Number of products:1)
Created by
admin on Fri Dec 15 16:46:45 GMT 2023 , Edited by admin on Fri Dec 15 16:46:45 GMT 2023
|
||
|
FDA ORPHAN DRUG |
782820
Created by
admin on Fri Dec 15 16:46:45 GMT 2023 , Edited by admin on Fri Dec 15 16:46:45 GMT 2023
|
||
|
CFR |
21 CFR 172.515
Created by
admin on Fri Dec 15 16:46:45 GMT 2023 , Edited by admin on Fri Dec 15 16:46:45 GMT 2023
|
||
|
FDA ORPHAN DRUG |
802320
Created by
admin on Fri Dec 15 16:46:45 GMT 2023 , Edited by admin on Fri Dec 15 16:46:45 GMT 2023
|
||
|
FDA ORPHAN DRUG |
783920
Created by
admin on Fri Dec 15 16:46:45 GMT 2023 , Edited by admin on Fri Dec 15 16:46:45 GMT 2023
|
||
|
JECFA EVALUATION |
CINNAMIC ACID
Created by
admin on Fri Dec 15 16:46:45 GMT 2023 , Edited by admin on Fri Dec 15 16:46:45 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
210-708-3
Created by
admin on Fri Dec 15 16:46:45 GMT 2023 , Edited by admin on Fri Dec 15 16:46:45 GMT 2023
|
ALTERNATIVE | |||
|
35697
Created by
admin on Fri Dec 15 16:46:45 GMT 2023 , Edited by admin on Fri Dec 15 16:46:45 GMT 2023
|
PRIMARY | |||
|
1368650
Created by
admin on Fri Dec 15 16:46:45 GMT 2023 , Edited by admin on Fri Dec 15 16:46:45 GMT 2023
|
PRIMARY | |||
|
140-10-3
Created by
admin on Fri Dec 15 16:46:45 GMT 2023 , Edited by admin on Fri Dec 15 16:46:45 GMT 2023
|
PRIMARY | |||
|
1368649
Created by
admin on Fri Dec 15 16:46:45 GMT 2023 , Edited by admin on Fri Dec 15 16:46:45 GMT 2023
|
PRIMARY | RxNorm | ||
|
100000090683
Created by
admin on Fri Dec 15 16:46:45 GMT 2023 , Edited by admin on Fri Dec 15 16:46:45 GMT 2023
|
PRIMARY | |||
|
623441
Created by
admin on Fri Dec 15 16:46:45 GMT 2023 , Edited by admin on Fri Dec 15 16:46:45 GMT 2023
|
PRIMARY | |||
|
444539
Created by
admin on Fri Dec 15 16:46:45 GMT 2023 , Edited by admin on Fri Dec 15 16:46:45 GMT 2023
|
PRIMARY | |||
|
23248
Created by
admin on Fri Dec 15 16:46:45 GMT 2023 , Edited by admin on Fri Dec 15 16:46:45 GMT 2023
|
PRIMARY | |||
|
187
Created by
admin on Fri Dec 15 16:46:45 GMT 2023 , Edited by admin on Fri Dec 15 16:46:45 GMT 2023
|
PRIMARY | |||
|
m3569
Created by
admin on Fri Dec 15 16:46:45 GMT 2023 , Edited by admin on Fri Dec 15 16:46:45 GMT 2023
|
PRIMARY | Merck Index | ||
|
44010
Created by
admin on Fri Dec 15 16:46:45 GMT 2023 , Edited by admin on Fri Dec 15 16:46:45 GMT 2023
|
PRIMARY | |||
|
27386
Created by
admin on Fri Dec 15 16:46:45 GMT 2023 , Edited by admin on Fri Dec 15 16:46:45 GMT 2023
|
PRIMARY | |||
|
CINNAMIC ACID
Created by
admin on Fri Dec 15 16:46:45 GMT 2023 , Edited by admin on Fri Dec 15 16:46:45 GMT 2023
|
PRIMARY | |||
|
U14A832J8D
Created by
admin on Fri Dec 15 16:46:45 GMT 2023 , Edited by admin on Fri Dec 15 16:46:45 GMT 2023
|
PRIMARY | |||
|
DTXSID5022489
Created by
admin on Fri Dec 15 16:46:45 GMT 2023 , Edited by admin on Fri Dec 15 16:46:45 GMT 2023
|
PRIMARY | |||
|
SUB29136
Created by
admin on Fri Dec 15 16:46:45 GMT 2023 , Edited by admin on Fri Dec 15 16:46:45 GMT 2023
|
PRIMARY | |||
|
1133933
Created by
admin on Fri Dec 15 16:46:45 GMT 2023 , Edited by admin on Fri Dec 15 16:46:45 GMT 2023
|
PRIMARY | |||
|
9189
Created by
admin on Fri Dec 15 16:46:45 GMT 2023 , Edited by admin on Fri Dec 15 16:46:45 GMT 2023
|
PRIMARY | |||
|
C029010
Created by
admin on Fri Dec 15 16:46:45 GMT 2023 , Edited by admin on Fri Dec 15 16:46:45 GMT 2023
|
PRIMARY | |||
|
U14A832J8D
Created by
admin on Fri Dec 15 16:46:45 GMT 2023 , Edited by admin on Fri Dec 15 16:46:45 GMT 2023
|
PRIMARY | |||
|
205-398-1
Created by
admin on Fri Dec 15 16:46:45 GMT 2023 , Edited by admin on Fri Dec 15 16:46:45 GMT 2023
|
PRIMARY | |||
|
621-82-9
Created by
admin on Fri Dec 15 16:46:45 GMT 2023 , Edited by admin on Fri Dec 15 16:46:45 GMT 2023
|
NON-SPECIFIC STEREOCHEMISTRY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> CONSTITUENT ALWAYS PRESENT |
USP
|
||
|
PARENT -> CONSTITUENT ALWAYS PRESENT |
Cinnamic acid content for water extract of plant leaf was 2.42+/-0.03 and plant callus was 0.76+/-0.59 as expressed as mg/100 g of dry base of extract.
For the analysis of phenolic acids, a Nova pack C18 UG120 equipped with a Guard column, a JASCO HPLC system consisting of a column oven, a UV-Vis diode array detector set at 280 nm, a Liquid chromatography pump and a ChromNAV software program were used.
|
||
|
PARENT -> CONSTITUENT ALWAYS PRESENT | |||
|
PARENT -> CONSTITUENT ALWAYS PRESENT | |||
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> METABOLITE |
|
||
|
METABOLITE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |